Please use this identifier to cite or link to this item:
|Title:||The burden of antibiotic allergies in adults in an Australian intensive care unit: the BASIS study.|
|Authors:||Moran, Rebekah L;Devchand, Misha;Churilov, Leonid;Warrillow, Stephen J;Trubiano, Jason A|
|Affiliation:||Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia|
Pharmacy Department, Austin Health, Heidelberg, Victoria, Australia
Department of Intensive Care, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
|Citation:||Critical Care and Resuscitation 2019; 21(4): 265-73|
|Abstract:||To determine the prevalence and impact of patient-reported antibiotic allergies in the intensive care unit (ICU), which are currently poorly defined. Antibiotic allergy labels (AALs) are associated with inappropriate antibiotic prescribing and with inferior patient, microbiological and hospital outcomes. Prospective, single-centre case-control study. Mixed ICU, Austin Hospital, Melbourne. All adults (≥ 18 years old) admitted to the ICU who received at least two doses of systemic antibiotics between 12 February and 20 April 2018. Demographic data, infection and allergy history, antibiotic prescriptions and ICU interventions and outcomes. Of the 247 patients (79.9%) who received systemic antibiotics, 43 patients (17.4%) had an AAL and 204 (82.6%) did not. A higher proportion of patients with AAL were female ( P = 0.032) and received vancomycin (37.2% AAL v 18.6% no antibiotic allergies [NAAL]; P = 0.014), and a lower proportion of patients received narrow spectrum β-lactams (39.5% AAL v 58.8% NAAL; P = 0.028). On multivariable logistic regression, the AAL cohort had twice higher odds of receiving vancomycin (odds ratio [OR], 2.04; 95% CI, 1.07-3.86; P = 0.029) and half the odds of receiving a narrow spectrum β-lactam (OR, 0.52; 95% CI, 0.29-0.94; P = 0.03). AAL distribution on the electronic medical record included 17% type A (predictable), 13% type B-I (immediate), 2% type B-IV (delayed), 35% type B (unspecified), and 32% unknown. An interview clarifying allergy phenotype found that 59.5% of AALs matched their documented description. Patients with AALs had twice the odds of receiving intravenous vancomycin and half the odds of receiving narrow spectrum β-lactams, which highlights the continued need for antimicrobial stewardship initiatives.|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.